Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]CUMI-101
- Development stage
- Unknown
- Lead developer
- Columbia University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[11C]CUMI-101 is a carbon-11 labeled radiopharmaceutical and small molecule that functions as a highly selective partial agonist for the serotonin 1A (5-HT1A) receptor. It was developed for use in positron emission tomography (PET) imaging to quantify the density and distribution of 5-HT1A receptors in the living human brain. Unlike traditional antagonist radiotracers like [11C]WAY-100635, [11C]CUMI-101 preferentially binds to receptors in their functional, high-affinity G-protein-coupled state. This characteristic makes it a valuable research tool for investigating endogenous serotonin release and receptor availability in neuropsychiatric conditions. It has been primarily evaluated in clinical research settings for disorders such as bipolar depression, major depressive disorder, and suicidal behavior to understand the biological mechanisms of serotonergic dysfunction.
- Other names
- 2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione[11C]-CUMI-101
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ADRA1A (α1A)
Beyond the preview
Go deeper on [11C]CUMI-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [11C]CUMI-101.